vs
PROCORE TECHNOLOGIES, INC.（PCOR）与Pacira BioSciences, Inc.（PCRX）财务数据对比。点击上方公司名可切换其他公司
PROCORE TECHNOLOGIES, INC.的季度营收约是Pacira BioSciences, Inc.的1.8倍（$349.1M vs $196.9M），PROCORE TECHNOLOGIES, INC.同比增速更快（15.6% vs 5.1%），PROCORE TECHNOLOGIES, INC.自由现金流更多（$109.2M vs $43.5M），过去两年PROCORE TECHNOLOGIES, INC.的营收复合增速更高（13.8% vs 8.5%）
Procore Technologies是2002年成立的美国建筑管理软件即服务（SaaS）企业，总部位于加利福尼亚州卡平特里亚。公司打造的全球平台可连接建筑行业从业者，支持搭建简化工作流，统一展现建筑项目信息，覆盖任务追踪、项目流程管理、日程排期等核心功能。
Pacira BioSciences是一家专科制药企业，专注于非阿片类疼痛管理药物的研发与商业化，核心产品线面向术后镇痛场景，服务以美国为主的医院、门诊手术中心等医疗服务机构，同时推进部分国际市场的拓展工作。
PCOR vs PCRX — 直观对比
营收规模更大
PCOR
是对方的1.8倍
$196.9M
营收增速更快
PCOR
高出10.4%
5.1%
自由现金流更多
PCOR
多$65.8M
$43.5M
两年增速更快
PCOR
近两年复合增速
8.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $349.1M | $196.9M |
| 净利润 | $-37.6M | — |
| 毛利率 | 80.1% | 79.5% |
| 营业利润率 | -12.3% | 1.2% |
| 净利率 | -10.8% | — |
| 营收同比 | 15.6% | 5.1% |
| 净利润同比 | 39.6% | — |
| 每股收益（稀释后） | $-0.25 | $0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PCORPCRX
| Q4 25 | $349.1M | $196.9M | ||
| Q3 25 | $338.9M | $179.5M | ||
| Q2 25 | $323.9M | $181.1M | ||
| Q1 25 | $310.6M | $168.9M | ||
| Q4 24 | $302.0M | $187.3M | ||
| Q3 24 | $295.9M | $168.6M | ||
| Q2 24 | $284.3M | $178.0M | ||
| Q1 24 | $269.4M | $167.1M |
净利润PCORPCRX
| Q4 25 | $-37.6M | — | ||
| Q3 25 | $-9.1M | $5.4M | ||
| Q2 25 | $-21.1M | $-4.8M | ||
| Q1 25 | $-33.0M | $4.8M | ||
| Q4 24 | $-62.3M | — | ||
| Q3 24 | $-26.4M | $-143.5M | ||
| Q2 24 | $-6.3M | $18.9M | ||
| Q1 24 | $-11.0M | $9.0M |
毛利率PCORPCRX
| Q4 25 | 80.1% | 79.5% | ||
| Q3 25 | 79.7% | 80.9% | ||
| Q2 25 | 79.1% | 77.4% | ||
| Q1 25 | 79.1% | 79.7% | ||
| Q4 24 | 81.2% | 78.7% | ||
| Q3 24 | 81.4% | 76.9% | ||
| Q2 24 | 83.1% | 75.1% | ||
| Q1 24 | 83.0% | 71.6% |
营业利润率PCORPCRX
| Q4 25 | -12.3% | 1.2% | ||
| Q3 25 | -4.4% | 3.5% | ||
| Q2 25 | -9.3% | 4.7% | ||
| Q1 25 | -11.7% | 1.2% | ||
| Q4 24 | -21.9% | 13.2% | ||
| Q3 24 | -12.3% | -82.8% | ||
| Q2 24 | -5.2% | 15.9% | ||
| Q1 24 | -7.0% | 7.9% |
净利率PCORPCRX
| Q4 25 | -10.8% | — | ||
| Q3 25 | -2.7% | 3.0% | ||
| Q2 25 | -6.5% | -2.7% | ||
| Q1 25 | -10.6% | 2.8% | ||
| Q4 24 | -20.6% | — | ||
| Q3 24 | -8.9% | -85.1% | ||
| Q2 24 | -2.2% | 10.6% | ||
| Q1 24 | -4.1% | 5.4% |
每股收益（稀释后）PCORPCRX
| Q4 25 | $-0.25 | $0.05 | ||
| Q3 25 | $-0.06 | $0.12 | ||
| Q2 25 | $-0.14 | $-0.11 | ||
| Q1 25 | $-0.22 | $0.10 | ||
| Q4 24 | $-0.42 | $0.38 | ||
| Q3 24 | $-0.18 | $-3.11 | ||
| Q2 24 | $-0.04 | $0.39 | ||
| Q1 24 | $-0.08 | $0.19 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $768.5M | $238.4M |
| 总债务越低越好 | — | $372.2M |
| 股东权益账面价值 | $1.3B | $693.1M |
| 总资产 | $2.2B | $1.3B |
| 负债/权益比越低杠杆越低 | — | 0.54× |
8季度趋势，按日历期对齐
现金及短期投资PCORPCRX
| Q4 25 | $768.5M | $238.4M | ||
| Q3 25 | $684.0M | $246.3M | ||
| Q2 25 | $620.9M | $445.9M | ||
| Q1 25 | $566.7M | $493.6M | ||
| Q4 24 | $775.4M | $484.6M | ||
| Q3 24 | $756.9M | $453.8M | ||
| Q2 24 | $735.4M | $404.2M | ||
| Q1 24 | $744.6M | $325.9M |
总债务PCORPCRX
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益PCORPCRX
| Q4 25 | $1.3B | $693.1M | ||
| Q3 25 | $1.2B | $727.2M | ||
| Q2 25 | $1.2B | $757.8M | ||
| Q1 25 | $1.2B | $798.5M | ||
| Q4 24 | $1.3B | $778.3M | ||
| Q3 24 | $1.3B | $749.6M | ||
| Q2 24 | $1.3B | $879.3M | ||
| Q1 24 | $1.2B | $892.2M |
总资产PCORPCRX
| Q4 25 | $2.2B | $1.3B | ||
| Q3 25 | $2.1B | $1.3B | ||
| Q2 25 | $2.0B | $1.5B | ||
| Q1 25 | $1.9B | $1.6B | ||
| Q4 24 | $2.1B | $1.6B | ||
| Q3 24 | $2.0B | $1.5B | ||
| Q2 24 | $2.0B | $1.6B | ||
| Q1 24 | $1.9B | $1.6B |
负债/权益比PCORPCRX
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $114.9M | $43.7M |
| 自由现金流经营现金流 - 资本支出 | $109.2M | $43.5M |
| 自由现金流率自由现金流/营收 | 31.3% | 22.1% |
| 资本支出强度资本支出/营收 | 1.6% | 0.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $282.2M | $136.7M |
8季度趋势，按日历期对齐
经营现金流PCORPCRX
| Q4 25 | $114.9M | $43.7M | ||
| Q3 25 | $88.5M | $60.8M | ||
| Q2 25 | $30.8M | $12.0M | ||
| Q1 25 | $66.0M | $35.5M | ||
| Q4 24 | $29.1M | $33.1M | ||
| Q3 24 | $39.3M | $53.9M | ||
| Q2 24 | $58.7M | $53.2M | ||
| Q1 24 | $69.1M | $49.1M |
自由现金流PCORPCRX
| Q4 25 | $109.2M | $43.5M | ||
| Q3 25 | $83.1M | $57.0M | ||
| Q2 25 | $27.9M | $9.3M | ||
| Q1 25 | $62.0M | $26.9M | ||
| Q4 24 | $17.4M | $31.0M | ||
| Q3 24 | $35.7M | $49.8M | ||
| Q2 24 | $56.8M | $51.6M | ||
| Q1 24 | $67.1M | $46.3M |
自由现金流率PCORPCRX
| Q4 25 | 31.3% | 22.1% | ||
| Q3 25 | 24.5% | 31.7% | ||
| Q2 25 | 8.6% | 5.1% | ||
| Q1 25 | 20.0% | 15.9% | ||
| Q4 24 | 5.8% | 16.6% | ||
| Q3 24 | 12.1% | 29.6% | ||
| Q2 24 | 20.0% | 29.0% | ||
| Q1 24 | 24.9% | 27.7% |
资本支出强度PCORPCRX
| Q4 25 | 1.6% | 0.1% | ||
| Q3 25 | 1.6% | 2.2% | ||
| Q2 25 | 0.9% | 1.5% | ||
| Q1 25 | 1.3% | 5.1% | ||
| Q4 24 | 3.9% | 1.1% | ||
| Q3 24 | 1.2% | 2.4% | ||
| Q2 24 | 0.7% | 0.9% | ||
| Q1 24 | 0.8% | 1.7% |
现金转化率PCORPCRX
| Q4 25 | — | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.82× | ||
| Q1 24 | — | 5.47× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PCOR
| US | $298.3M | 85% |
| Non Us | $50.9M | 15% |
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |
